CHLORTHALIDONE

Post-LOE

Abbott

ANDAORALTABLET

Approved

Mar 1981

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

CHLORTHALIDONE by Abbott is clinical pharmacology chlorthalidone is an oral diuretic with prolonged action (48–72 hours) and low toxicity. Approved for the management of hypertension either alone, combination with other antihypertensive drugs, pregnancy and 2 more indications. First approved in 1981.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Chlorthalidone is an oral diuretic with prolonged action (48–72 hours) and low toxicity. The major portion of the drug is excreted unchanged by the kidneys. The diuretic effect of the drug occurs in approximately 2.6 hours and continues for up to 72 hours. The mean half-life…

Indications (5)

the management of hypertension either alone

Worked on CHLORTHALIDONE at Abbott? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (14)

NCT02521246Phase 3Withdrawn

Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

Started Nov 2016

Essential Arterial Hypertension

NCT02521233Phase 3Withdrawn

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Started Nov 2016

Essential Arterial Hypertension

NCT03226340Phase 4Unknown

S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

Started Dec 2015

170 enrolled

Essential Hypertension

NCT01456169Phase 3Completed

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Started Oct 2011

507 enrolled

Essential Hypertension

NCT01368536Phase 4Terminated

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Started May 2011

975 enrolled

HypertensionStage 2 HypertensionDiabetes